OPKO Health (NASDAQ:OPK) Earns “Outperform” Rating from Barrington Research

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reissued by research analysts at Barrington Research in a report released on Friday, Benzinga reports. They presently have a $2.25 target price on the biotechnology company’s stock. Barrington Research’s price target would suggest a potential upside of 48.51% from the company’s current price.

A number of other research firms have also recently issued reports on OPK. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday. Finally, StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research report on Saturday, July 27th.

OPKO Health Price Performance

Shares of OPKO Health stock traded down $0.08 on Friday, reaching $1.52. 2,081,892 shares of the stock were exchanged, compared to its average volume of 7,699,669. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The firm has a market cap of $1.06 billion, a PE ratio of -4.33 and a beta of 1.64. The firm’s 50 day moving average is $1.52 and its 200-day moving average is $1.33. OPKO Health has a one year low of $0.85 and a one year high of $1.75.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $184.70 million. During the same period in the previous year, the business earned ($0.03) earnings per share. The company’s revenue was down 31.3% on a year-over-year basis. As a group, analysts anticipate that OPKO Health will post -0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $26.63, for a total value of $1,331,500.00. Following the completion of the transaction, the insider now owns 3,508,603 shares in the company, valued at approximately $93,434,097.89. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold a total of 736,644 shares of company stock valued at $23,874,134 in the last 90 days. Corporate insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. increased its position in shares of OPKO Health by 11.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock worth $931,000 after buying an additional 79,525 shares during the period. Moseley Investment Management Inc. acquired a new stake in OPKO Health during the 1st quarter worth about $41,000. Tidal Investments LLC acquired a new stake in OPKO Health during the 1st quarter worth about $239,000. Y.D. More Investments Ltd bought a new position in shares of OPKO Health in the 2nd quarter worth about $1,840,000. Finally, Comerica Bank lifted its stake in shares of OPKO Health by 125.0% in the 1st quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 50,000 shares during the period. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.